Table 1.
Sample Characteristics.
| Characteristics | Chemotherapy group (n = 28) | Non-chemotherapy group (n = 37) | Control group (n = 32) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| no. | Mean | SD | no. | Mean | SD | no. | Mean | SD | |
| Age at Pre-treatment baseline, years | 50 | 10 | 53 | 9 | 50 | 9 | |||
| Education years* | 15 | 2 | 15 | 2 | 17 | 2 | |||
| MMSE | 29 | 1 | 29 | 1 | 30 | 1 | |||
| PHQ-8 | 4 | 4 | 4 | 4 | 3 | 3 | |||
| Days from Surgery to Pre-treatment assessment* | 24 | 9 | 36 | 17 | |||||
| Days from Pre- to Post-treatment assessment | 169 | 41 | 168 | 35 | 174 | 41 | |||
| Race | |||||||||
| White | 22 | 34 | 28 | ||||||
| Non-white | 6 | 3 | 4 | ||||||
| Cancer stage* | |||||||||
| 0 (DCIS) | 0 | 11 | - | ||||||
| I | 5 | 20 | - | ||||||
| II | 16 | 6 | - | ||||||
| IIIa | 7 | 0 | - | ||||||
| Type of surgery* | |||||||||
| Lumpectomy | 15 | 35 | - | ||||||
| Mastectomy | 13 | 2 | - | ||||||
| Lymph node dissection* | 16 | 2 | |||||||
| Received psychiatric medication | |||||||||
| Pre-treatment | 5 | 5 | 7 | ||||||
| Post-treatment | 5 | 7 | 7 | ||||||
| Chemotherapy regimen | |||||||||
| Doxorubicin/cyclophosphamide | 1 | - | - | ||||||
| Doxorubicin/cyclophosphamide/paclitaxel | 22 | ||||||||
| Docetaxel/cyclophosphamide | 5 | - | - | ||||||
| Received radiotherapy (Post-treatment)* | 16 | 37 | - | ||||||
| Received endocrine therapy (Post-treatment)* | 8 | 32 | - | ||||||
| Menstrual status at baseline | |||||||||
| Pre | 14 | 12 | 10 | ||||||
| Peri | 2 | 5 | 7 | ||||||
| Post | 12 | 20 | 15 | ||||||
| Hemoglobin (g/dl) | |||||||||
| Pre-treatment* | 12.8 | 0.8 | 13.7 | 0.7 | 13.3 | 0.9 | |||
| Post-treatment* | 12.3 | 1.1 | 13.4 | 0.8 | 13.2 | 0.8 | |||
Abbreviations: MMSE=Mini Mental State Exam; PHQ=Patient Health Questionnaire; DCIS=ductal carcinoma in situ; g/dl=grams/deciliter.
*
p < .05 for significant between-group difference in a one-way ANOVA for continuous variables, and in a chi-square test for categorical variables.
One chemotherapy participant, 1 non-chemotherapy participant, and 3 control participants were missing hemoglobin values at pre-treatment assessment. Two chemotherapy participants, 1 non-chemotherapy participant, and 2 control participants were missing hemoglobin values at post-treatment assessment.